KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Other financing activities: 2019-2022

Historic Other financing activities for Halozyme Therapeutics (HALO) over the last 3 years, with Dec 2022 value amounting to $7.1 million.

  • Halozyme Therapeutics' Other financing activities was N/A to $639,000 in Q4 2022 from the same period last year, while for Dec 2022 it was $7.2 million, marking a year-over-year change of. This contributed to the annual value of $7.1 million for FY2022, which is 1575.47% up from last year.
  • As of FY2022, Halozyme Therapeutics' Other financing activities stood at $7.1 million, which was up 1,575.47% from $424,000 recorded in FY2021.
  • Halozyme Therapeutics' 5-year Other financing activities high stood at $7.1 million for FY2022, and its period low was $279,000 during FY2019.
  • Over the past 2 years, Halozyme Therapeutics' median Other financing activities value was $3.8 million (recorded in 2021), while the average stood at $3.8 million.
  • Data for Halozyme Therapeutics' Other financing activities shows a peak YoY skyrocketed of 1,575.47% (in 2022) over the last 5 years.
  • Halozyme Therapeutics' Other financing activities (Yearly) stood at $279,000 in 2019, then reached $424,000 in 2021, then surged by 1,575.47% to $7.1 million in 2022.